BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17. [PMID: 27231906 DOI: 10.3390/ijms17060803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Sharma DL, Lakhani HV, Klug RL, Snoad B, El-Hamdani R, Shapiro JI, Sodhi K. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis. J Clin Cell Immunol 2017;8:523. [PMID: 29177105 DOI: 10.4172/2155-9899.1000523] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
2 Lim DW, Kim H, Lee SJ, Yu GR, Kim JE, Park WH. Jwa Kum Whan Attenuates Nonalcoholic Fatty Liver Disease by Modulating Glucose Metabolism and the Insulin Signaling Pathway. Evid Based Complement Alternat Med 2019;2019:4589810. [PMID: 30881473 DOI: 10.1155/2019/4589810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Debebe A, Medina V, Chen CY, Mahajan IM, Jia C, Fu D, He L, Zeng N, Stiles BW, Chen CL, Wang M, Aggarwal KR, Peng Z, Huang J, Chen J, Li M, Dong T, Atkins S, Borok Z, Yuan W, Machida K, Ju C, Kahn M, Johnson D, Stiles BL. Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis. Oncogene 2017;36:6020-9. [PMID: 28671671 DOI: 10.1038/onc.2017.207] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
4 Koletzko L, Mahli A, Hellerbrand C. Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism. Pathol Res Pract 2018;214:1700-6. [PMID: 30201523 DOI: 10.1016/j.prp.2018.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Doycheva I, Zhang T, Amjad W, Thuluvath PJ. Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. J Clin Exp Hepatol 2020;10:296-303. [PMID: 32655232 DOI: 10.1016/j.jceh.2019.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019;25:56-67. [PMID: 30609189 DOI: 10.1002/lt.25338] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
8 Shirasaki T, Murai K, Honda M, Okada H, Innami Y, Yamada A, Shimakami T, Kawaguchi K, Yamashita T, Sakai Y, Kaneko S. Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice. Sci Rep 2021;11:13021. [PMID: 34158541 DOI: 10.1038/s41598-021-92128-9] [Reference Citation Analysis]
9 Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PMID: 29359341 DOI: 10.1111/apt.14521] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
10 Guaraldi G, Lonardo A, Maia L, Palella FJ Jr. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS 2017;31 Suppl 2:S147-56. [PMID: 28471945 DOI: 10.1097/QAD.0000000000001483] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
11 Murai K, Honda M, Shirasaki T, Shimakami T, Omura H, Misu H, Kita Y, Takeshita Y, Ishii KA, Takamura T, Urabe T, Shimizu R, Okada H, Yamashita T, Sakai Y, Kaneko S. Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity. Cell Host Microbe 2019;25:588-601.e7. [PMID: 30974086 DOI: 10.1016/j.chom.2019.02.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Nițescu M, Vâjâitu C, Săndulescu O, Streinu-cercel A, Pițigoi D, Preoțescu LL, Streinu-cercel A. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. Revista Romana de Medicina de Laborator 2017;25:355-63. [DOI: 10.1515/rrlm-2017-0030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019;15:e1008181. [PMID: 31216276 DOI: 10.1371/journal.pgen.1008181] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 16.3] [Reference Citation Analysis]
14 Spearman CW, Abdo A, Ambali A, Awuku YA, Kassianides C, Lesi OA, Ndomondo-Sigonda M, Onyekwere CA, Rwegasha J, Shewaye AB, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1047-56. [PMID: 34508669 DOI: 10.1016/S2468-1253(21)00296-X] [Reference Citation Analysis]
15 Dunn W, Vittal A, Zhao J, He J, Chakraborty S, Whitener M, Fohn S, Ash R, Taylor RM, Olyaee M, Olson JC, Todd N, Floyd BN, Pandya P, Laycock M, Schmitt T, Weinman SA. PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis. BMJ Open Gastroenterol 2019;6:e000241. [PMID: 30997139 DOI: 10.1136/bmjgast-2018-000241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Mihai C, Mihai B, Trifan A, Stanciu C, Gheorghe L, Diculescu M, Curescu M, Brisc C, Goldis A, Bataga S, Sandulescu L, Rogoveanu I, Seicean A, Cijevschi Prelipcean C. Metabolic Syndrome and Genotype 1 Virus C Compensated Liver Cirrhosis in the Era of Directly Acting Antiviral Therapy. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.58022] [Reference Citation Analysis]
17 Magri MC, Manchiero C, Prata TVG, Nunes AKDS, Oliveira Junior JS, Dantas BP, Tengan FM. The influence of gene-chronic hepatitis C virus infection on hepatic fibrosis and steatosis. Diagn Microbiol Infect Dis 2020;97:115025. [PMID: 32147132 DOI: 10.1016/j.diagmicrobio.2020.115025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Gatzios A, Rombaut M, Buyl K, De Kock J, Rodrigues RM, Rogiers V, Vanhaecke T, Boeckmans J. From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines 2022;10:161. [DOI: 10.3390/biomedicines10010161] [Reference Citation Analysis]
19 Gallotta A, Paneghetti L, Mrázová V, Bednárová A, Kružlicová D, Frecer V, Miertus S, Biasiolo A, Martini A, Pontisso P, Fassina G. Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients. Int J Biol Markers 2018;33:231-6. [PMID: 29712495 DOI: 10.1177/1724600817753577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01055-7. [PMID: 34624564 DOI: 10.1016/j.cgh.2021.09.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Brunt EM. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation. Hepatol Commun. 2017;1:370-378. [PMID: 29404465 DOI: 10.1002/hep4.1055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
22 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
23 Sasaki R, Sur S, Cheng Q, Steele R, Ray RB. Repression of MicroRNA-30e by Hepatitis C Virus Enhances Fatty Acid Synthesis. Hepatol Commun 2019;3:943-53. [PMID: 31334444 DOI: 10.1002/hep4.1362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Perez S, Gevor M, Davidovich A, Kaspi A, Yamin K, Domovich T, Meirson T, Matityahu A, Brody Y, Stemmer SM, El-Osta A, Haviv I, Onn I, Gal-Tanamy M. Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions. Nucleic Acids Res 2019;47:2455-71. [PMID: 30698808 DOI: 10.1093/nar/gkz052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Yi Z, Yuan Z. Hepatitis C Virus-Associated Cancers. Adv Exp Med Biol. 2017;1018:129-146. [PMID: 29052135 DOI: 10.1007/978-981-10-5765-6_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight 2018;3:120274. [PMID: 30046009 DOI: 10.1172/jci.insight.120274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
27 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
28 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
29 Pernes G, Lancaster GI, Murphy AJ. Take me to the liver: adipose tissue macrophages coordinate hepatic neutrophil recruitment. Gut 2018;67:1204-6. [PMID: 29298875 DOI: 10.1136/gutjnl-2017-315393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Komura T, Ohta H, Seike T, Shimizu Y, Nakai R, Omura H, Kagaya T, Kasashima S, Kawashima A, Oba S, Harada K, Kaneko S, Unoura M. The Efficacy of Corticosteroid Therapy in a Patient with Non-alcoholic Steatohepatitis Overlapping Autoimmune Hepatitis. Intern Med 2018;57:807-12. [PMID: 29151501 DOI: 10.2169/internalmedicine.8887-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Barrouin-Melo SM, Morejón Terán YA, Anturaniemi J, Hielm-Björkman AK. Interaction Between Nutrition and Metabolism. Exp Suppl 2018;109:29-114. [PMID: 30535598 DOI: 10.1007/978-3-319-74932-7_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Viganò L, Lleo A, Aghemo A. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario. Hepatobiliary Surg Nutr 2018;7:130-3. [PMID: 29744343 DOI: 10.21037/hbsn.2018.01.01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
34 Coronel-Castillo CE, Qi X, Contreras-Carmona J, Ramírez-Pérez OL, Méndez-Sánchez N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease. Expert Rev Gastroenterol Hepatol 2019;13:531-40. [PMID: 30905208 DOI: 10.1080/17474124.2019.1599284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
35 Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction? J Clin Med 2021;10:924. [PMID: 33804296 DOI: 10.3390/jcm10050924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Qin J, Higashi T, Nakagawa S, Fujiwara N, Yamashita YI, Beppu T, Baba H, Kobayashi M, Kumada H, Gunasekaran G, Schiano TD, Thung SN, Fiel MI, Hoshida Y, Ward SC. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights. Am J Surg Pathol 2020;44:1406-12. [PMID: 32618599 DOI: 10.1097/PAS.0000000000001533] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Nirei K, Matsumura H, Kumakawa M, Matsumoto N, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci 2017;14:45-52. [PMID: 28138308 DOI: 10.7150/ijms.17202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
38 Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 2019;101:154005. [PMID: 31711876 DOI: 10.1016/j.metabol.2019.154005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 18.0] [Reference Citation Analysis]
39 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
40 Hagymási K, Egresi A, Lengyel G. [Extrahepatic manifestations in chronic hepatitis C infected patients]. Orv Hetil 2017;158:603-11. [PMID: 28415864 DOI: 10.1556/650.2017.30751] [Reference Citation Analysis]
41 Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. J Formos Med Assoc 2021;120:68-77. [PMID: 32654868 DOI: 10.1016/j.jfma.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Gai XD, Wu WF. Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis. Exp Ther Med 2017;14:3908-14. [PMID: 29043000 DOI: 10.3892/etm.2017.4963] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
43 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]